Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis

Stroke

Volumn 43, Issue 12, 2012, Pages 3395-3398

  Ford, Andria L ^a   Williams, Jennifer A ^c   Spencer, Mary ^c   McCammon, Craig ^c   Khoury, Naim ^a   Sampson, Tomoko R ^a   Panagos, Peter ^a   Lee, Jin Moo ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

Acute stroke protocol; Door to needle time; Lean manufacturing; Thrombolytic; TPA; Value stream analysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; DOOR TO NEEDLE TIME; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SAFETY; POINT OF CARE TESTING; PRIORITY JOURNAL; PROCESS TECHNOLOGY; TIME; VALUE STREAM ANALYSIS; WATCHFUL WAITING; WORKFLOW;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; EFFICIENCY, ORGANIZATIONAL; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INDUSTRY; MALE; MIDDLE AGED; MODELS, ORGANIZATIONAL; PATIENT CARE TEAM; PROGRAM EVALUATION; REGISTRIES; STROKE; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84870955513     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.670687     Document Type: Article

References (11)

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet. 2004;363:768-774.
2. Mikulik R, Kadlecova P, Czlonkowska A, Kobayashi A, Brozman M, Svigelj V, et al. Factors influencing in-hospital delay in treatment with intravenous thrombolysis. Stroke. 2012;43:1578-1583.
3. Smaha LA. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148:S46-S48.
4. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda M V, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750-758.
5. Ohno T. The Toyota Production System: Beyond Large-Scale Production. Portland, OR: Productivity Press; 1988.
6. Ng D, Vail G, Thomas S, Schmidt N. Applying the lean principles of the Toyota production system to reduce wait times in the emergency department. Can J Emerg Med. 2010;12:50-57.
7. Teichgraber UK, de Bucourt M. Applying value stream mapping techniques to eliminate non-value-added waste for the procurement of endovascular stents. Eur J Radiol. 2012;81:e47-e52.
8. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The 'golden hour' and acute brain ischemia: presenting features and lytic therapy in >30 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-1439.
9. Chernyshev OY, Martin-Schild S, Albright KC, Barreto A, Misra V, Acosta I, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010;74:1340-1345.
10. Winkler DT, Fluri F, Fuhr P, Wetzel SG, Lyrer PA, Ruegg S, et al. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke. 2009;40:1522-1525.
11. Artto V, Putaala J, Strbian D, Meretoja A, Piironen K, Liebkind R, et al. Stroke mimics and intravenous thrombolysis. Ann Emerg Med. 2012;59:27-32.